Detalles de la búsqueda
1.
ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.
Nat Immunol
; 24(7): 1161-1172, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37322179
2.
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.
N Engl J Med
; 384(20): 1899-1909, 2021 05 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33951374
3.
Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.
N Engl J Med
; 384(20): 1885-1898, 2021 05 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33725432
4.
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial.
Lancet
; 399(10323): 461-472, 2022 01 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-35065705
5.
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
Lancet
; 397(10269): 99-111, 2021 01 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-33306989
6.
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.
Lancet
; 397(10277): 881-891, 2021 03 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33617777
7.
Immunogenicity and safety of beta variant COVID-19 vaccine AZD2816 and AZD1222 (ChAdOx1 nCoV-19) as primary-series vaccination for previously unvaccinated adults in Brazil, South Africa, Poland, and the UK: a randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study.
Lancet Microbe
; 2024 Jun 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38878794
8.
Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19.
Viruses
; 15(2)2023 02 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36851662
9.
Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
Lancet Infect Dis
; 23(3): 295-306, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36273491
10.
Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).
Vaccine
; 41(23): 3486-3492, 2023 05 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-37149443
11.
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial.
Lancet HIV
; 9(5): e309-e322, 2022 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-35489376
12.
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
Lancet HIV
; 8(9): e568-e580, 2021 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-34416193
13.
14.
15.
Resultados
1 -
15
de 15
1
Próxima >
>>